A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Completed

Plain-English translation of NCT03677141 on ClinicalTrials.gov ↗ · Source last updated December 2024 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

Trial locations(41 sites)

United States

University of Alabama Birmingham, Birmingham, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

University of California; Moores Cancer Center, La Jolla, California

University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica, Santa Monica, California

Georgetown University Medical Center, Washington D.C., District of Columbia